Article Sidebar

PDF
Date Published: 06/10/2024
Abstract Views: 2
Views PDF: 1
DOI: https://doi.org/10.56535/jmpm.v49si1.946
Issue
Vol. 49 No. si1 (2024): TẠP CHÍ Y DƯỢC HỌC QUÂN SỰ - SỐ ĐẶC BIỆT 10/2024
Section
Hội nghị Khoa học Ghép tạng toàn quốc lần thứ IX
How to Cite
Nguyen, T. T. H., Bui Van Manh, & Le Viet Thang, L. V. T. (2024). DE NOVO HLA - DSA IN PATIENTS WITH KIDNEY FUNCTION REDUCTION IN THE FIRST 6 MONTHS AFTER TRANSPLANTATION. Journal of Military Pharmaco-medicine, 49(si1), 84-92. https://doi.org/10.56535/jmpm.v49si1.946

DE NOVO HLA - DSA IN PATIENTS WITH KIDNEY FUNCTION REDUCTION IN THE FIRST 6 MONTHS AFTER TRANSPLANTATION

Nguyen Thi Thu Ha1, , Bui Van Manh 1, Le Viet Thang Le Viet Thang1
1 Học viện Quân y

Main Article Content

Abstract

Objectives: Survey characteristics of de novo HLA - DSA and study of the relationship with some clinical and paraclinical characteristics in patients with reduced kidney function in the first 6 months after transplantation. Methods: Prospective, cross-sectional, follow-up after transplantation. Results: The incidence of de novo HLA - DSA after kidney transplantation was 33.3% (with a mean MFI of 1442). The level of HLA compatibility < 3/6 was associated with de novo HLA-DSA after transplantation (p < 0.05). The occurrence of proteinuria after kidney transplantation was associated with a 22-fold higher risk of de novo HLA-DSA (OR = 22.25; p < 0.05). Conclusion:  The ratio of de novo HLA - DSA appearing after transplantation in patients with reduced kidney function is high. The low level of HLA compatibility and the appearance of proteinuria after transplantation are related to the appearance of de novo HLA – DSA.

Article Details

Keywords

HLA – DSA, Kidney function reduction, The first months after transplantation.

References

1. Smith JD, Banner NR, Hamour IM, et al. De novo donor HLA-specific antibodies after heart transplantation are an independent predictor of poor patient survival. Am J Transplant. 2011; 11(2):312-319.
2. Tikkanen JM, Singer LG, Kim SJ, et al. De Novo DQ donor-specific antibodies are associated with chronic lung allograft dysfunction after lung transplantation. Am J Respir Crit Care Med. 2016; 194(5):596-606.
3. Zhang R. Donor-specific antibodies in kidney transplant recipients. Clin J Am Soc Nephrol. 2018; 13(1):182-192.
4. Worthington JE, Martin S, Al-Husseini DM, et al. Posttransplantation production of donor HLA-specific antibodies as a predictor of renal transplant outcome. Transplantation. 2003; 75(7):1034-40.
5. Hoshino J, Kaneku H, Everly MJ, et al. Using donor-specific antibodies to monitor the need for immunosuppression. Transplantation. 2012; 93(11):1173-1178.
6. Devos JM, Gaber AO, Teeter LD, et al. Intermediate-term graft loss after renal transplantation is associated with both donor-specific antibody and acute rejection. Transplantation. 2014; 97(5):534-540.
7. Alagoz S and Seyahi N. Frequency of human leukocyte antigens and donor specific antibodies in long-term living donor kidney transplantation. Transplant Proc. 2019; 51(7):2302-2307.
8. Kwon H, Kim YH, Kim JY, et al. The results of HLA-incompatible kidney transplantation according to pre-transplant crossmatch tests: Donor-specific antibody as a prominent predictor of acute rejection. Clin Transplant. 2019; 33(5):e13533.
9. Jalalonmuhali M, Carroll RP, Tsiopelas E, et al. Development of de novo HLA donor specific antibodies (HLA-DSA), HLA antibodies (HLA-Ab) and allograft rejection post blood transfusion in kidney transplant recipients. Hum Immunol. 2020; 81(7): 323-329.
10. Rusai K, Dworak J, Potemkina A, et al. Donor-specific HLA antibodies and graft function in kidney-transplanted children - the Vienna cohort. Pediatr Transplantation. 2016; 20:507-514.